Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Maria Weimer

Neurology with Special Qualifications in Child Neurology New Orleans, LA Medical Doctor

NPI 1659394518 CMS profile 666858

200 Henry Clay Ave, Children's Hospital - Neurology, New Orleans, LA 70118

Open in the dashboard

General payments

$5,772

239 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Maria Weimer of New Orleans, LA is reported in the CMS Open Payments database as having received $5,772 across 239 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 76th percentile of Neurology with Special Qualifications in Child Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $812 28
2024 General $879 27
2023 General $1,145 36
2022 General $926 35
2021 General $830 37
2020 General $458 29
2019 General $722 47

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Maria Weimer
  • Neurology with Special Qualifications in Child Neurology median
  • Middle half of Neurology with Special Qualifications in Child Neurology
  • National median

In program year 2025, general payments to Maria Weimer were reported at $812. Among 1,228 Neurology with Special Qualifications in Child Neurology profiles paid that year, the median was $276 and the middle half received between $87 and $1,522.

Show as a table
Year Maria Weimer Neurology with Special Qualifications in Child Neurology median Middle half National median
2019 $722 $262 $68–$1,313 $163
2020 $458 $188 $46–$1,222 $114
2021 $830 $183 $45–$1,356 $132
2022 $926 $229 $72–$1,177 $149
2023 $1,145 $269 $93–$1,195 $160
2024 $879 $300 $98–$1,428 $164
2025 $812 $276 $87–$1,522 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. UCB, Inc. $855 29 payments
  2. Eisai Inc. $435 21 payments
  3. SK Life Science, Inc. $411 12 payments
  4. Neurelis, Inc. $394 11 payments
  5. Jazz Pharmaceuticals Inc. $391 14 payments
  6. Supernus Pharmaceuticals, Inc. $367 30 payments
  7. PTC Therapeutics, Inc. $343 16 payments
  8. Sarepta Therapeutics, Inc. $300 14 payments
  9. Biogen, Inc. $280 13 payments
  10. Sunovion Pharmaceuticals Inc. $204 15 payments
  11. Other $1,791 64 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,772 239 payments
Products named General payments · program years 2019–2025
  1. Epidiolex $480 18 payments
  2. Briviact $476 18 payments
  3. Fycompa $435 21 payments
  4. VALTOCO $394 11 payments
  5. OXTELLAR XR $355 29 payments
  6. Fintepla $305 8 payments
  7. EMFLAZA $296 14 payments
  8. Evrysdi $258 7 payments
  9. SPINRAZA $240 11 payments
  10. APTIOM $204 15 payments
  11. Other $2,245 80 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

14

Median for Neurology: 833

Drug cost

$32,785

Median for Neurology: $202,670

Branded share of claims

100%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxtellar Xr Oxcarbazepine Brand 14 $32,785

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 14 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VALTOCO
  • Neurelis, Inc. $153
$153 — —
VYVGART
  • ARGENX US, INC. $115
$115 — —
Epidiolex
  • JAZZ PHARMACEUTICALS INC. $85
$85 — —
Briviact
  • UCB, Inc. $62
$62 — —
DIACOMIT
  • BIOCODEX, INC. $55
$55 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 14 in the dashboard with a free account

Records

239 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology with Special Qualifications in Child Neurology in Louisiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record